The combination of tamoxifen, a drug used for the initial treatment and prevention of estrogen-receptor-positive (ER+) breast tumors, and genistein synergized in vitro inhibition of the growth of ER+/HER2-overexpressing BT-474 human BC cells. This evidence concerns the gene ESR1 and breast neoplasm.